Live
- MP BJP to celebrate former PM Vajpayee's birth anniversary on Dec 25
- Christmas Eve 2024: Heartwarming Messages To Share With Your Loved Ones
- PM Modi holds brainstorming session with economists in run-up to Budget
- “Telangana Ready to Support AI Technologies That Drive Social Impact,” says Special Chief Secy, Jayesh Ranjan at Woxsen University’s Future Tech Summit 2024
- Hero Motosports Team Rally Announces Squad For Dakar Rally 2025
- Two Men Found Dead In Parked Caravan In Kerala
- Mandhana moves closer to top spot in ODI, T20I rankings
- IND vs AUS Boxing Day Test 2024: Sam Konstas Debuts, Travis Head’s Fitness in Question
- Congress Challenges Election Rule Amendments In Supreme Court
- Jaishankar’s US Visit: Key Diplomatic Engagement Amid Leadership Transition
Aurobindo Pharma gets warning letter from FDA
Drug firm Aurobindo Pharma on Friday said it has received a warning letter from the US health regulator for one of its units in Srikakulam district, Andhra Pradesh, which was the subject of an inspection earlier this year.
Hyderabad: Drug firm Aurobindo Pharma on Friday said it has received a warning letter from the US health regulator for one of its units in Srikakulam district, Andhra Pradesh, which was the subject of an inspection earlier this year.
The company has received a warning letter from the United States Food and Drug Administration (USFDA) relating to our unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam District, Andhra Pradesh.
This action follows the earlier inspection of the site by the USFDA in February 2019, Aurobindo Pharma said in a BSE filing.
Aurobindo Pharma said it "believes the existing business from this facility will not be impacted". The drug firm, however, did not provide any details of the contents of the warning letter received from the regulator.
"We will be engaging with the regulator and are fully-committed in resolving this issue at the earliest. The company is also committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe," the company added.
Meanwhile, shares of the company fell by nearly 4 per cent on Friday after the company received the warning letter.
The scrip declined 3.92 per cent to close at Rs 602.35 on the BSE. During the day, it dropped 7.68 per cent to Rs 578.75.
On NSE, shares of the company fell by 3.85 per cent to close at Rs 603. In terms of traded volume, 4.47 lakh shares of the company changed hands on the BSE and over 74 lakh shares were traded on the NSE during the day.
